Trial Profile
A Randomized, Parallel Control, Exploratory Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in Subjects With Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 13 Jan 2017 New trial record